These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2660932)

  • 1. Results of long-term subcutaneous desferrioxamine therapy.
    Hoffbrand AV; Wonke B
    Baillieres Clin Haematol; 1989 Apr; 2(2):345-62. PubMed ID: 2660932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
    Janka GE; Möhring P; Helmig M; Haas RJ; Betke K
    Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
    Pippard MJ; Jackson MJ; Hoffman K; Petrou M; Modell CB
    Scand J Haematol; 1986 May; 36(5):466-72. PubMed ID: 3738427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 7. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 17. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-thalassaemia--the Johannesburg experience.
    Poole JE; Cohn RJ; Roode H; Spector I
    S Afr Med J; 1989 Apr; 75(8):367-70. PubMed ID: 2652340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
    Tillmann W; König R; Schröder K; Schröter W
    Monatsschr Kinderheilkd; 1982 Mar; 130(3):171-2. PubMed ID: 7087975
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.